MA40057A - Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants - Google Patents

Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants

Info

Publication number
MA40057A
MA40057A MA040057A MA40057A MA40057A MA 40057 A MA40057 A MA 40057A MA 040057 A MA040057 A MA 040057A MA 40057 A MA40057 A MA 40057A MA 40057 A MA40057 A MA 40057A
Authority
MA
Morocco
Prior art keywords
skin
therapeutic
tratment
abnormal skin
microorganisms
Prior art date
Application number
MA040057A
Other languages
English (en)
French (fr)
Inventor
Azim Momin Munivar
Travis Michael Whitfill
Original Assignee
Azitra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azitra filed Critical Azitra
Publication of MA40057A publication Critical patent/MA40057A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
MA040057A 2014-05-30 2015-05-28 Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants MA40057A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462005558P 2014-05-30 2014-05-30
US201462005652P 2014-05-30 2014-05-30

Publications (1)

Publication Number Publication Date
MA40057A true MA40057A (fr) 2015-12-03

Family

ID=54699800

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040057A MA40057A (fr) 2014-05-30 2015-05-28 Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants

Country Status (6)

Country Link
US (3) US10702558B2 (enExample)
EP (2) EP4144756A1 (enExample)
JP (2) JP6810028B2 (enExample)
ES (1) ES2929579T3 (enExample)
MA (1) MA40057A (enExample)
WO (1) WO2015184134A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2929579T3 (es) 2014-05-30 2022-11-30 Azitra Inc Tratamiento terapéutico de enfermedades cutáneas con microorganismos cutáneos comensales recombinantes
WO2017184992A1 (en) 2016-04-21 2017-10-26 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
WO2018232300A1 (en) * 2017-06-16 2018-12-20 Azitra Inc Compositions and methods for treatment of netherton syndrome with lekti expressing recombinant microbes
EP3675884A4 (en) * 2017-08-31 2021-08-11 The Regents of the University of California MOLECULAR BACTERIOTHERAPY TO CONTROL ENZYMATIC ACTIVITY OF THE SKIN
KR20250111396A (ko) * 2017-09-05 2025-07-22 아지트라 인코포레이티드 재조합 미생물을 사용하여 염증성 피부 질환을 치료하기 위한 방법 및 조성물
JP7460531B2 (ja) 2017-12-05 2024-04-02 バイオピーエルエックス，インコーポレイティド 微生物感染を防ぐための方法および組成物
JP7121969B2 (ja) * 2018-02-23 2022-08-19 株式会社北里コーポレーション 培養液保護用液状物
JP2021528041A (ja) * 2018-04-05 2021-10-21 アジトラ インコーポレーテッド 組換え微生物を用いて皮膚疾患を処置するための方法および組成物
AU2019203692B2 (en) * 2018-08-30 2024-12-12 Kenvue Brands Llc Topical composition containing glycerin and yeast extract
AU2019346461B2 (en) * 2018-09-26 2026-01-22 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
WO2020076770A1 (en) * 2018-10-08 2020-04-16 Yale University Selective binding and aggregation of human keratin in the skin barrier using human filaggrin subdomains sd67 and sd150
JP2022513599A (ja) * 2018-11-16 2022-02-09 アジトラ インコーポレーテッド Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ細菌の栄養要求性株
CZ308231B6 (cs) * 2019-02-11 2020-03-11 BiomCare s.r.o. Kombinované několikastupňové mikrobiální přípravky a způsob jejich aplikace
EP3946412A4 (en) * 2019-04-05 2023-01-04 Azitra, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF ATOPIC DERMATITIS WITH RECOMBINANT MICROORGANISMS
US20220362358A1 (en) * 2019-06-19 2022-11-17 Chan Zuckerberg Biohub, Inc. Bacteria-engineered to elicit antigen-specific t-cells
US20230087622A1 (en) * 2020-01-29 2023-03-23 The Jackson Laboratory Bacterial admixtures
KR20230088803A (ko) * 2020-10-21 2023-06-20 더 잭슨 래보라토리 항미생물성 바이오센서
JP2024506463A (ja) * 2021-01-05 2024-02-14 ラクトバイオ アー／エス 菌株、組成物および使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637384B2 (ja) * 1985-09-21 1994-05-18 株式会社資生堂 皮膚化粧料
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE4221255C2 (de) 1992-06-26 1994-09-15 Lancaster Group Ag Phospholipide enthaltendes Kosmetikum
DE4221268C2 (de) 1992-06-26 1997-06-12 Lancaster Group Ag Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut
NO2480669T3 (enExample) * 2009-09-25 2018-04-07
EP2504357B1 (en) 2009-11-23 2017-08-02 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
US20130078275A1 (en) * 2010-05-25 2013-03-28 The Board Of Trustees Of The University Of Illinois Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells
AU2013299605A1 (en) * 2012-08-07 2015-03-26 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
KR101491240B1 (ko) 2013-03-15 2015-02-11 현대자동차주식회사 인비저블 슬라이딩 도어 링크 구조
ES2929579T3 (es) 2014-05-30 2022-11-30 Azitra Inc Tratamiento terapéutico de enfermedades cutáneas con microorganismos cutáneos comensales recombinantes

Also Published As

Publication number Publication date
US20210379120A1 (en) 2021-12-09
EP3148569A4 (en) 2017-11-22
US20250009810A1 (en) 2025-01-09
CA2979079A1 (en) 2015-12-03
JP6810028B2 (ja) 2021-01-06
JP2017518370A (ja) 2017-07-06
US12036248B2 (en) 2024-07-16
US20180161380A1 (en) 2018-06-14
ES2929579T3 (es) 2022-11-30
US10702558B2 (en) 2020-07-07
EP4144756A1 (en) 2023-03-08
JP2021038271A (ja) 2021-03-11
EP3148569B1 (en) 2022-07-06
WO2015184134A1 (en) 2015-12-03
EP3148569A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
MX2018005588A (es) Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno.
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
SG10201811185YA (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
EP3818991A3 (en) Compositions and methods for treating diseases
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
WO2011090297A3 (ko) 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
MX357071B (es) Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes.
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
MX2017001433A (es) Sistema de bioprocesamiento a microescala y metodo para fabricacion de proteina a partir de sangre humana.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases
MD4763B1 (ro) Compoziţie farmaceutică
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
IN2013MN01547A (enExample)